HK1252771A1 - 用於治療眼部病狀的玻璃體內藥物遞送系統 - Google Patents

用於治療眼部病狀的玻璃體內藥物遞送系統

Info

Publication number
HK1252771A1
HK1252771A1 HK18112132.4A HK18112132A HK1252771A1 HK 1252771 A1 HK1252771 A1 HK 1252771A1 HK 18112132 A HK18112132 A HK 18112132A HK 1252771 A1 HK1252771 A1 HK 1252771A1
Authority
HK
Hong Kong
Prior art keywords
treatment
drug delivery
delivery systems
ocular conditions
intravitreal drug
Prior art date
Application number
HK18112132.4A
Other languages
English (en)
Inventor
Stuart Williams
Sanjib Das
Tomas Navratil
Melissa Sandahl
Janet Tully
Rozemarijn Verhoeven
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of HK1252771A1 publication Critical patent/HK1252771A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112132.4A 2015-07-23 2018-09-20 用於治療眼部病狀的玻璃體內藥物遞送系統 HK1252771A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562196269P 2015-07-23 2015-07-23
US201662277281P 2016-01-11 2016-01-11
US201662329763P 2016-04-29 2016-04-29
US201662358372P 2016-07-05 2016-07-05

Publications (1)

Publication Number Publication Date
HK1252771A1 true HK1252771A1 (zh) 2019-05-31

Family

ID=57834773

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112132.4A HK1252771A1 (zh) 2015-07-23 2018-09-20 用於治療眼部病狀的玻璃體內藥物遞送系統

Country Status (8)

Country Link
US (2) US10624904B2 (zh)
EP (1) EP3324944A4 (zh)
JP (3) JP6914931B2 (zh)
CN (2) CN115337254A (zh)
AU (2) AU2016297187A1 (zh)
CA (1) CA2993340C (zh)
HK (1) HK1252771A1 (zh)
WO (1) WO2017015604A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
US20200306182A1 (en) * 2019-03-05 2020-10-01 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
US20220133532A1 (en) * 2020-11-04 2022-05-05 Aerie Pharmaceuticals, Inc. Medical implant
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405713A (en) 1966-10-24 1968-10-15 Solowey Ida Combination hypodermic needle blocker and needle sheath
US4251310A (en) 1977-11-25 1981-02-17 Baxter Travenol Laboratories, Inc. Method for rebonding tubing elements used in needle assemblies
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129710A (en) 1997-05-12 2000-10-10 Spectrum Biotech Inc. Needle cannula attachment device for a disposable syringe
US7468065B2 (en) 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US20040151754A1 (en) 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
EP1670480A4 (en) * 2003-02-20 2007-10-10 Alcon Inc USE OF STEORIDES IN THE TREATMENT OF OCULAR DISORDERS
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US7998108B2 (en) 2006-09-12 2011-08-16 Psivida Us, Inc. Injector apparatus and method of use
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100278897A1 (en) 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US20110229551A1 (en) 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
WO2012043544A1 (ja) 2010-09-29 2012-04-05 テルモ株式会社 針付きシリンジ
JP5704389B2 (ja) 2010-11-29 2015-04-22 ニプロ株式会社 医療用中空針および医療用中空針の製造方法
US8945214B2 (en) 2011-12-19 2015-02-03 Allergan, Inc. Intravitreal applicator
US9554940B2 (en) 2012-03-26 2017-01-31 Glaukos Corporation System and method for delivering multiple ocular implants
CA2882184C (en) 2012-08-27 2021-09-07 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using microneedles
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
TWI686213B (zh) * 2013-03-21 2020-03-01 美商優普順藥物公司美國分部 可注射持續釋放組合物及使用其治療關節之發炎及與發炎有關之疼痛之方法
ES2834964T3 (es) * 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
US9492316B2 (en) 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
KR20220082934A (ko) * 2013-11-15 2022-06-17 알레간 인코포레이티드 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
US20160067426A1 (en) 2014-09-10 2016-03-10 Shweta A. Ujaoney Lighted Syringe Shrouding Device
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
CA3036993A1 (en) 2016-09-02 2018-03-08 Aerie Pharmaceuticals, Inc. Implant applicators

Also Published As

Publication number Publication date
JP2018521144A (ja) 2018-08-02
US20200230157A1 (en) 2020-07-23
CN115337254A (zh) 2022-11-15
CA2993340C (en) 2024-04-30
AU2019240562B2 (en) 2021-10-14
JP2023120431A (ja) 2023-08-29
CN108883070A (zh) 2018-11-23
AU2016297187A1 (en) 2018-02-15
JP6914931B2 (ja) 2021-08-04
US10624904B2 (en) 2020-04-21
US20190083512A1 (en) 2019-03-21
WO2017015604A1 (en) 2017-01-26
US11116776B2 (en) 2021-09-14
AU2019240562A1 (en) 2019-10-17
EP3324944A4 (en) 2019-04-03
CA2993340A1 (en) 2017-01-26
JP2021143191A (ja) 2021-09-24
EP3324944A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
HK1252836A1 (zh) 水凝膠藥物遞送
ZA201807048B (en) Medical delivery system
SG10202012083YA (en) Liquid delivery system
FI3581226T3 (fi) Järjestelmät hoitokaasun toimittamista varten
GB201913962D0 (en) Ophthalmic drug compositions
HK1252771A1 (zh) 用於治療眼部病狀的玻璃體內藥物遞送系統
HK1258518A1 (zh) 用於眼病的基因療法
GB201408561D0 (en) Aerosolisation engine for liquid drug delivery
GB201515650D0 (en) Medicament delivery devices
IL253461A0 (en) Hydrogels for the release of therapeutic compounds
IL256327A (en) Pharmacological preparations for the treatment of viral problems of the eye
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
EP3377011A4 (en) LASER-ASSISTED MEDICAMENT DELIVERY SYSTEM
EP3471829A4 (en) DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTIVIRAL AGENTS
EP3454868A4 (en) ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
HUE057487T2 (hu) Gyógyszeradagoló rendszer
HK1256875A1 (zh) 加强對大腦的藥物輸送
EP3302443A4 (en) MECHANO SENSITIVE MICRO CAPSULES FOR DRUG DELIVERY
IL274920B1 (en) Maytansinoid-based drug delivery systems
GB201419540D0 (en) Delivery of drugs
IL246874A0 (en) drug delivery system
EP3474836C0 (en) OPHTHALMIC MEDICINE CONTAINING SALBUTAMOL.
EP3217947A4 (en) Kidney-targeted drug delivery systems
GB201412842D0 (en) Catheter for the delivery of therapeutic fluid
GB201721832D0 (en) Ocular drug delivery